Harvest One (TSXV:HVT, OTCQX: HRVOF), through it’s wholly-owned subsidiary Satipharm Ltd. (“Satipharm”) today announced that it has entered into an agreement to distribute their proprietary Satipharm CBD 10mg Gelpell® through Holland & Barrett, Europe’s largest retailer of nutritional supplements and wellness products with over 145 years of experience in the health and wellness industry.

Under the terms of the agreement, Harvest One will supply Satipharm CBD 10mg Gelpell® to 841 Holland Barrett stores and online via the Holland & Barret website. An initial shipment, which arrived on June 5th, 2019, will be distributed to stores across the UK. Satipharm will be supporting this increase in distribution with education and product training.


“This supply agreement is pivotal to our global strategy. Having a European health and wellness leader like Holland & Barrett trust and carry our product shows the investment in our manufacturing standards and commercial strategy is proving a success” said Grant Froese, CEO of Harvest One. “We plan to build on this valued agreement by growing the demand for Satipharm CBD Gelpell® capsules through both instore and online activity.”

“The CBD industry is growing rapidly. We will continue to be at the forefront of that growth through the release of innovative products that can add value to the market” said a spokesperson for Holland & Barrett. “Satipharm CBD Gelpell® capsules give our customers a consistent measurable dose of CBD that can be easily taken throughout their day.”

Satipharm does CBD differently. Satipharm CBD Gelpell® capsules contain full spectrum hemp extract CBD in a seamless gelatine bead. This bead is placed inside a hard gastro-resistant capsule ensuring the release of CBD in the small intestine. This EU GMP certified product is manufactured in Switzerland to the highest standards under controlled laboratory conditions ensuring that every Satipharm CBD Gelpell® capsule delivers a consistent dose of CBD. Satipharm’s product has undergone Stage I and Stage II clinical trials and is proven to have 30% higher bioavailability than other products on the market.

This agreement provides Harvest One’s wholly owned subsidiary Satipharm, a European platform for growth with Satipharm CBD Gelpell® capsules now available in most cities across the UK and Ireland.

About Satipharm

Satipharm is a health and wellness company which is specialised in the development and manufacture of cannabinoid-based products from the hemp plant. Our mission is to deliver the highest quality products that are designed specifically with the needs of our customers in mind.

About Holland &Barrett

Holland & Barrett International is one of the world’s leading health and wellness retailers and the largest in Europe, supplying its customers with a wide range of vitamins, minerals, health supplements, specialist foods and natural beauty products. With over 145 years of experience in the industry, the Holland & Barrett name is a familiar sight in almost every major city and town across the UK and is becoming increasingly more visible further afield, in markets as diverse as the Netherlands and Malta to the UAE, China and India with more than 1,300 stores across the Globe. For more information visit www.hollandandbarrett.com.

About Harvest One

Harvest One is a global company that develops and provides innovative lifestyle and wellness products to consumers and patients in regulated markets around the world. The Company’s range of lifestyle solutions is designed to enhance quality of life.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.

Click here to connect with Harvest One (TSXV:HVT) for an Investor Presentation. 

Source: www.prnewswire.com

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less

 Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.

For more information regarding the Company or the offering, please contact ir@hillstreetbevco.com, or

Keep reading... Show less